Silence Therapeutics plc (SLN)
NASDAQ: SLN · Real-Time Price · USD
19.79
+0.04 (0.20%)
At close: Nov 10, 2026, 4:00 PM EST
19.59
-0.20 (-0.99%)
After-hours: Nov 10, 2026, 5:36 PM EST
Silence Therapeutics Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Silence Therapeutics stock has a consensus rating of "Hold" and an average price target of $19.75. The average 1-year stock price forecast is 0.20% lower than the current stock price, while the lowest is $19 (-3.99%) and the highest is $20 (+1.06%).
Price Target: $19.75 (-0.20%)
Analyst Consensus: Hold
Price Target
ChartAnalyst Ratings
The average analyst rating for Silence Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 5 | 5 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Total | 6 | 7 | 7 | 7 | 7 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Hold Downgrades $75 → $20 | Hold | Downgrades | $75 → $20 | +1.06% | Oct 21, 2026 |
| Jefferies | Jefferies | Hold Downgrades $35 → $20 | Hold | Downgrades | $35 → $20 | +1.06% | Oct 19, 2026 |
| William Blair | William Blair | Hold Downgrades n/a | Hold | Downgrades | n/a | n/a | Oct 19, 2026 |
| Chardan Capital | Chardan Capital | Hold Downgrades $27 → $20 | Hold | Downgrades | $27 → $20 | +1.06% | Oct 19, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Reiterates $25 → $32 | Buy | Reiterates | $25 → $32 | +61.70% | Aug 11, 2026 |
Financial Forecast
Revenue This Year
439.30K
from 559.00K
Decreased by -21.41%
Revenue Next Year
1.02M
from 439.30K
Increased by 131.31%
EPS This Year
-0.36
EPS Next Year
-0.38
from -0.36
EPS and Forward PE are based on non-GAAP adjusted numbers.